Multiple Sclerosis Therapeutics to Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth

Transcription

1 Brochure More information from Multiple Sclerosis Therapeutics to Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Description: Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of $4 billion in Over the forecast period , a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mabs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mabs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, the authors believe the global market has the potential to grow to a value of $17.9 billion by Scope - A brief introduction to MS, including the disease's history, pathogenesis, risk factors and diagnosis. - In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy. - Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of latestage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes. - Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration. - Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology. - Discussion of the drivers and barriers for market growth or decay. Reasons to buy - Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS. - Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent. - Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics. - Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs. - Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market. Contents: 1 Table of Contents 1.1 List of Tables 1.2 List of Figures

2 2 Introduction 2.1 Disease Overview 2.2 Epidemiology 2.3 Symptoms 2.4 Etiology 2.5 Pathophysiology Blood Brain Barrier Degradation Cellular Infiltration of the Central Nervous System 2.6 Co-morbidities/Complications 2.7 Diagnosis McDonald Criteria Physical Examination MRI Scans Lumbar Puncture Other Diagnostic Tests 2.8 Prognosis 2.9 Treatment Efficacy 2.10 Treatment Options Corticosteroids Anti-neoplastic Drugs Skeletal Muscle Relaxants Pain Management in MS 2.11 Treatment Algorithm 2.12 Non-pharmacological Therapies 3 Therapeutic Landscape 3.1 Copaxone (glatiramer acetate) Teva Pharmaceuticals 3.2 Betaseron (interferon beta 1b) Bayer AG 3.3 Avonex (interferon beta 1a IM) Biogen 3.4 Rebif (interferon beta 1a SC) Merck Serono 3.5 Tysabri (natalizumab) Biogen Idec/Elan Corporation 3.6 Gilenya (fingolimod hydrochloride) Mitsubishi Tanabe and Novartis 3.7 Aubagio (Teriflunomide) Genzyme Corporation and Sanofi-Aventis 3.8 Novantrone (mitoxantrone ) Merck Serono 3.9 Conclusion 3.10 Unmet Need 4 Pipeline for Multiple Sclerosis Therapeutics 4.1 Overall Pipeline 4.2 Route of Administration 4.3 Molecular Targets within the MS Pipeline 4.4 Clinical Trials Failure Rate of Developmental Programs Clinical Trial Size Clinical Trial Duration 4.5 Promising Pipeline Candidates Lemtrada (alemtuzumab) Genzyme and Bayer Schering Pharma Tecfidera (dimethyl fumarate) Biogen Idec Laquinimod (laquinimod sodium) Teva Pharmaceuticals ocrelizumab F. Hoffman-La Roche daclizumab Biogen Idec and Abbot Laboratories firategrast GlaxoSmithKline Siponimod (BAF-312) Novartis AG 4.6 Conclusion 5 Market Forecast to Geographical Markets Key Developed Markets US Top Five EU Countries Japan 5.2 Drivers and Barriers Drivers

3 5.2.2 Barriers 6 Deals and Strategic Consolidations 6.1 Major Co-development Deals Daiichi Sankyo Enters into an Agreement with Amplimmune Karo Bio Enters into an Agreement with Pfizer Proteostasis Enters into an Agreement with Elan Lycera Enters into an Agreement with Merck Facet Enters into an Agreement with Trubion UCB Enters into an Agreement with Biogen 6.2 Major Licensing Deals Addex Extends its Licensing Agreement with Merck Biogen Enters into a Licensing Agreement with Acorda Therapeutics Genzyme Enters into a Licensing Agreement with Bayer Healthcare Novartis Enters into a Licensing Agreement with Peptimmune Merck Serono Enters into a Licensing Agreement with Apitope Technology Antisense Enters into a Licensing Agreement with Teva Pharmaceutical BioMS Medical Corp Enters into a Licensing Agreement with Eli Lilly Biotica Enters into an Agreement with Wyeth 7 Appendix 7.1 Pipeline Product Tables by Phase 7.2 Market Forecasting Data Tables to Market Definition 7.4 Abbreviations 7.5 References 7.6 Methodology 7.7 Secondary Research 7.8 Therapeutic Landscape 7.9 Epidemiology-Based Forecasting 7.10 Market Size by Geography 7.11 Pipeline Analysis 7.12 Contact Us 7.13 Disclaimer 1.1 List of Tables Table 1: McDonald Criteria, Multiple Sclerosis, 2013 Table 2: Expanded Disability Status Scale, Multiple Sclerosis, 2013 Table 3: Multiple Sclerosis, Global, Market Forecast, ($bn), Table 4: Multiple Sclerosis, US, Market Forecast, ($bn), Table 5: Multiple Sclerosis, UK, Market Forecast, ($bn), Table 6: Multiple Sclerosis, France, Market Forecast, ($bn), Table 7: Multiple Sclerosis, Germany, Market Forecast, ($bn), Table 8: Multiple Sclerosis, Italy, Market Forecast, ($bn), Table 9: Multiple Sclerosis, Spain, Market Forecast, ($bn), Table 10: Multiple Sclerosis, Japan, Market Forecast, ($bn), List of Figures Figure 1: Treatment Algorithm, Global, Multiple Sclerosis, 2013 Figure 2: Multiple Sclerosis, Marketed Products Heat Map Figure 3: Overall Pipeline for Multiple Sclerosis Figure 4: Routes of Administration in the Pipeline Figure 5: Molecular Targets of Pipeline Molecules Figure 6: Molecular Targets in MS Pipeline by Phase of Development Figure 7: Failure Rate of MS Clinical Trials, Figure 8: Reasons for Clinical Trial Failure, Figure 9: Clinical Trial Size by Product and Phase, Figure 10: Clinical Trial Duration by Phase and Molecule Type, Figure 11: Multiple Sclerosis, Pipeline Product Heat Map Figure 12: Multiple Sclerosis, Marketed Product Heat Map, Figure 13: Multiple Sclerosis Market, Global, Patient Volumes ( 000) and Market Size ($bn),

4 Figure 14: Multiple Sclerosis Market, US, Patient Volumes ( 000), Annual Cost of Treatment ($) and Market Size ($bn), Figure 15: Multiple Sclerosis Market, EU5, Patient Population ( 000), Figure 16: Multiple Sclerosis Market, EU5, Annual Cost of Treatment ($), Figure 17: Multiple Sclerosis Market, EU5, Market Size ($bn), Figure 18: Multiple Sclerosis Market, Japan, Patient Volume ( 000), Annual Cost of Treatment ($) and Market Size ($bn), Figure 19: Multiple Sclerosis, Co-development Deals by Geography, Value and Year, Figure 20: Multiple Sclerosis, Co-Development Deal Frequency by Phase and Molecule Type Figure 21: Multiple Sclerosis, Licensing Deals by Geography, Value and Year, Figure 22: Multiple Sclerosis, Licensing Deal frequency by Phase and Molecule Type, Figure 23: Multiple Sclerosis, Licensing Deal Value by Molecule Type and Mechanism of Action, Figure 24: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Discovery) Figure 25: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-I Figure 26: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-II Figure 27: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-III Figure 28: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -I Figure 29: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -II Figure 30: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - I Figure 31: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - II Figure 32: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase III) Figure 33: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Registration) Figure 34: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Undisclosed) Figure 35: Multiple Sclerosis Market, Global, GBI Research Market Sizing Model Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

5 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Web Address: Office Code: Multiple Sclerosis Therapeutics to Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth SC Product Formats Please select the product formats and quantity you require: Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 3500 USD 7000 USD Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

6 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World